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A large volume of epidemiological data have established 
that body mass index (BMI), as an approximation of gen­
eral adiposity, is a risk factor for several, but not all, 
common cancers1,2. However, there is as yet only indi­
rect evidence that reversal of excess weight (for exam­
ple, through bariatric surgery) reduces the risk of cancer 
incidence3, and the effect of such interventions may be 
observable only after a decade. In the meantime, a bet­
ter understanding of the biological mechanisms under­
pinning this link might identify intermediary biomarkers 
of cancer risk and potential new preventive strategies. As 
the prevalence of overweight and obesity have inexora­
bly risen in developed and less­developed countries in 
the past three decades, addressing the prevention of can­
cers attributed to excess adiposity is a globally important 
health problem4.
In their seminal review in 2004, Calle and Kaaks5 pro­
posed three ‘hormonal’ candidate mechanisms for the 
adiposity–cancer link: altered sex hormone metabolism, 
increased insulin levels and bioavailability of insulin­like 
growth factor I (IGF1), and adipokine pathophysiology. 
In the intervening years, the mechanism of adipokine 
pathophysiology has been expanded to include systemic 
(subclinical) inflammation. In this Review, we first pro­
vide an update on the epidemiological evidence on the 
associations between BMI and cancer risk, in an attempt 
to identify clues about different prevailing mechanisms 
for the increased risk of cancer according to different sites, 
gender, geographical populations, histological subtypes 
and molecular phenotypes. Second, we summarize the 
aforementioned candidate mechanisms and highlight sev­
eral shortfalls to these hypotheses. Third, we summarize 
the effect of weight­losing interventions on intermediary 
biomarkers from the above candidate systems. Fourth, we 
describe in more detail how epidemiology has informed 
the emerging importance of body fat distribution, par­
ticularly local ectopic fat, as a para crine mechanism for 
cancer development. Finally, we turn to future directions 
and examine how new technologies may better define 
body fat compartments at population levels. As a prelude, 
TABLE 1 summarizes current methods for measuring body 
adiposity and body fat distribution6.
BMI and cancer risk
Specificity of BMI–cancer associations. The sec­
ond report of the World Cancer Research Fund and 
American Institute for Cancer Research (WCRF/AICR) 
global perspective2 in 2007 concluded that there was 
“convincing” evidence that body fatness, generally 
measured by calculating BMI, was associated with an 
increased risk of oesophageal adenocarcinoma and can­
cers of the pancreas, colorectum, postmenopausal breast, 
endometrium and kidney, and evidence of a “probable” 
association of body fatness with increased risk of gall­
bladder cancer. Simultaneously, we reported a systematic 
review and dose–response meta­analysis of prospective 
cohort studies (221 datasets including 281,137 incident 
cancer diagnoses) quantifying incident relative risk 
for increases of 20 cancer types, expressed per 5 kg per m2
increase in BMI1. By using a standardized approach 
across a large number of cancer types, our analysis dem­
onstrated that BMI–cancer associations are: sex specific 
(for example, the risk of developing colon cancer is more 
pronounced for men than for women); site specific (for 
example, the risk of developing colon cancer is more 
pronounced than that of rectal cancer); histology spe­
cific (for example, an association exists for oesophageal 
adenocarcinoma but not for oesophageal squamous cell 
Body mass index
(BMI). An anthropometric 
measure of body adiposity 
defined as the body mass  
(in kilograms) divided by the 
square of the body height  
(in metres).
Intermediary biomarkers 
Biomarkers that predict the 
development of a disease and 
thought to be on the causal 
pathway to the development of 
that disease.
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Abstract | Excess body adiposity, commonly expressed as body mass index (BMI), is a risk 
factor for many common adult cancers. Over the past decade, epidemiological data have 
shown that adiposity–cancer risk associations are specific for gender, site, geographical 
population, histological subtype and molecular phenotype. The biological mechanisms 
underpinning these associations are incompletely understood but need to take account of 
the specificities observed in epidemiology to better inform future prevention strategies.
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Sex hormone
A family of hormones that 
share a basic chemical 
(steroidal) structure. These 
hormones include androgens, 
oestrogens and progesterone, 
and they have important 
effects on sexual development 
and reproductive functions.
Bioavailability
The proportion of a substance 
that can be used physiologically 
by target tissues.
Cohort studies
Studies in which a group of 
individuals is investigated 
prospectively over time. This is 
the preferred epidemiological 
study method for evaluating 
anthropometric measures and 
cancer risk.
Relative risk
The risk of cancer (or other 
disease) in a group of exposed 
persons divided by the risk in a 
group of unexposed persons. 
Relative risk is a commonly 
used measure of association in 
epidemiological studies. 
Effect modification
Also known as effect 
interaction. When the 
association of an exposure with 
the risk of disease differs in the 
presence of another exposure.
carcinoma (SCC)); and broadly consistent across geo­
graphical populations, with some notable exceptions 
of specificity (for example, there is an increased risk of 
premenopausal breast cancer in Asia­Pacific populations 
but not North American and European populations). 
This analysis also demonstrated that BMI–cancer risk 
associations exist for a wider range of malignancies than 
previously thought, including thyroid cancer, malignant 
melanoma in men, multiple myeloma, leukaemia and 
non­Hodgkin lymphoma.
Subsequent updated dose–response meta­analyses, 
using data mainly from prospective studies, reported 
positive associations between BMI and subsequent 
increased risk of pancreatic cancer (after taking account 
of the effect modification of smoking, discussed below)7, 
ovarian cancer (after taking account of the effect modi­
fication of hormone replacement therapy (HRT), dis­
cussed below)8,9 and Hodgkin lymphoma10. Single­study 
reports indicate modest associations between BMI and 
bladder cancer11 and increased BMI in early adulthood 
and glioma risk12; a meta­analysis showed no associations 
between BMI and testicular cancer13.
A recently published large analysis of the UK Clinical 
Practice Research Dataset, which includes 5.24 million 
individuals with 166,955 new cancers (of 22 types), 
corrob orated many of the above findings for many can­
cer types and with similar risk estimates14. Importantly, 
as this was a ‘same population’ analysis, the authors were 
able to observe within­population heterogeneity in the 
effects of BMI on the risk of developing multiple cancer 
types, and they speculate that “different mechanisms 
are associated with different cancer sites and different 
patient subgroups”.
When the relationship between BMI and risk of all 
prostate cancer is examined, risk estimates generally 
show no association1, or even show an inverse associa­
tion14, and there is often considerable between­study 
heterogeneity . Previously, there had been debate about 
whether such heterogeneity reflects effect modification 
due to different levels of prostate­specific antigen (PSA; 
also known as KLK3) screening across different popula­
tions and for different periods of time15. In recent years, 
the relationship between BMI (and indeed, other anthro-
pometric measures) and prostate cancer risk has become 
clearer. Specifically, there is considerable evidence from 
prospective cohorts demonstrating that increased BMI 
is associated with increased risk of advanced­stage pros­
tate cancer16,17. TABLE 2 summarizes gender­specific sum-
mary risk estimates per 5 kg per m2 increase in BMI for 
those cancers for which the evidence for an association 
is strongest18.
Adult weight gain is also associated with incident 
risk of cancer. A recently reported dose–response meta­
analysis of 50 prospective studies demonstrated that 
patterns of association between adult weight gain and 
cancer incidence mirror those for BMI and cancer19. As 
adult weight gain correlates with later­adulthood BMI 
(cohort baseline), and this is the BMI value most com­
monly determined in epidemiological studies assessing 
BMI–cancer associations, it is unclear whether adult 
weight gain is more informative for assessing cancer risk 
than BMI per se.
Effect modifications of BMI–cancer associations. 
There are three cancer types for which the associations 
between BMI and cancer risk are consistently inverse: 
Table 1 | Anthropometric measurements of adiposity used in the assessment of disease risk
Measure Classifications Parameters* Correlations*‡ Comments
BMI 
(commonly 
expressed Δ: 
5 kg per m2)
• Underweight: <18.5 kg per m2§
• Normal weight: 18.5–24.9 kg per m2
• Overweight: 25.0–29.9 kg per m2
• Obese I: 30.0–34.9 kg per m2
• Obese II: 35.0–39.9 kg per m2
• Obese III: ≥40.0 kg per m2
Mean (sd):
• M: 27.6 (4.6) kg per m2
• W: 27.1 (5.6) kg per m2
Height: rho = 0.26 Self-reported results tend to 
underestimate BMI in heavier 
individuals and with advancing age; 
BMI is a poor indicator among the 
elderly
WC 
(commonly 
expressed Δ: 10 cm)
• M: >102 cm§
• W: >88 cm§
Mean (sd):
• M: 98.8 (12.5) cm
• W: 87.8 (13.6) cm
BMI: rho = 0.46 There are multiple WC measurement 
protocols, although these do not 
influence associations with outcome
WHR 
(commonly 
expressed Δ: 0.1)
• M: >0.90§
• W: >0.85§
Mean (sd):
• M: 0.93 (0.07)
• W: 0.82 (0.07)
• BMI: rho = 0.33
• WC: rho = 0.93
WHR better reflects weight changes 
in men than in women; similar to 
WC, increased WHR predicts for risk 
of diabetes and CVD
HC 
(commonly 
expressed Δ: 10 cm)
None Mean (sd):
• M: 105.6 (8.2) cm
• W: 106.3 (11.5) cm
• BMI: rho = 0.47
• WC: rho = 0.90
• WHR: rho = 0.73
Increased HC predicts for a reduced 
risk of CVD
Fat distribution • Abdominal adiposity as SAT and VAT 
• Ectopic fat depots
Multi-detector CT scan; 
whole MR imaging
Correlations with 
WC:
• SAT: rho ≈ 0.88
• VAT: rho ≈ 0.74
SAT is frequently a stronger 
determinant of WC than VAT
NAFLD Steatosis, NASH, inflammation, injury, 
fibrosis and miscellaneous
Histology MR spectroscopy; 
chemical-shift MR
Key determinant of insulin resistance
BMI, body mass index; CT, computed tomography; CVD, cardiovascular disease; HC, hip circumference; M, men; MR, magnetic resonance; NAFLD, nonalcoholic 
fatty liver disease; NASH, nonalcoholic steatohepatitis; SAT, subcutaneous adipose tissue; sd, standard deviation; VAT, visceral adipose tissue; W, women; WC, waist 
circumference; WHR, waist/hip ratio. *Data from Health Survey for England 2006 to 2009. Individual person data aged 20 to 74 years, total: 34,417 (M: 15,553;  
W: 18,864)6. ‡Spearman correlations with rho values. §Based on World Health Organization definitions.
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Anthropometric measures
Measurements of the size or 
proportions of the human 
body: for example, weight, 
height and waist circumference.
Summary risk estimates
The weighted summations of 
collections of study-level risks 
derived from meta-analyses of 
studies. These estimates are 
typically reported as risk or 
point estimates with 95% 
confidence intervals.
Confounding
The association or lack of 
association with an exposure 
that is actually due to another 
factor that determines the 
occurrence of a disease but 
that is also associated with the 
exposure.
Anovulation
A menstrual cycle that is not 
accompanied by the discharge 
of an egg from the ovary.
lung cancer, oesophageal SCC, and head and neck can­
cers. It is now established that cigarette smoking is an 
effect modifier of the associations between BMI and 
lung cancer14,20 and between BMI and oesophageal 
SCC21, and it is the most likely explanation for the posi­
tive association between leanness and increased risk of 
head and neck cancers22,23. Given that mean BMI val­
ues are generally lower in ever smokers than in never 
smokers24, and that smoking is a strong risk factor for 
lung cancer and oesophageal SCC, the observed inverse 
associations probably reflect confounding or, in adjusted 
analy ses, residual confounding by smoking25. In the 
absence of smoking, associations between BMI and these 
cancers are probably close to null. Smoking also affects 
the association between BMI and pancreatic cancer7, but 
in this case there is a positive association between BMI 
and cancer risk in the absence of smoking, whereas there 
is no association in the presence of smoking.
An additional effect modifier of BMI–cancer risk 
associations is HRT. The risk estimates between BMI 
and cancer stratified by HRT use are shown in TABLE 3 
for postmenopausal breast26, endometrial27 and ovar­
ian8 cancers. In all three cancer types, associations 
between BMI and cancer risk are strongest for never 
HRT users, and associations are attenuated among ever 
users. The type of HRT (oestrogen alone versus com­
bined oestrogen and progesterone) does not seem to 
be important. This suggests that endogenous sex hor­
mones are on the causal pathway between adiposity 
and occurrence of these cancers; when these pathways 
are diluted in the relatively elevated doses of exogenous 
sex hormones in HRT, BMI–cancer risk associations 
are less pronounced.
BMI and premenopausal breast cancer. The case of adi­
posity and premenopausal breast cancer risk deserves 
specific mention. Data from prospective studies con­
sistently report an inverse association between BMI 
and premenopausal breast cancer risk (approximately 
10% reduced risk per 5 kg per m2), in North American 
and European populations1,28. Conventionally, this is 
explained by ovarian­derived androgen excess and 
chronic anovulation, and an associated reduction of 
luteal­phase progesterone production (proges terone 
deficiency). This hypothesis is supported by two 
analyses of the serum levels of various sex hormones 
in large prospective cohorts29,30, which reported that 
excess androgen levels were associated with increased 
premenopausal breast cancer risk.
However, it is incorrect to assume that this asso­
ciation presents a ‘protective’ effect of female sex 
hormones. Alternative explanations, including 
methodological reasons, may exist. Thus, by con­
trast, among women from Asia­Pacific populations, 
increased BMI is associated with an increased risk 
of premenopausal breast cancer (approximately 15% 
increased risk per 5 kg per m2)1,31. Additionally, among 
women from North American and European popula­
tions, associations between anthropometric measures 
of abdominal fatness (such as waist circumference 
(WC) and waist/hip ratio (WHR)) and premeno­
pausal breast cancer risk are generally null or modestly 
positive32–34. Collectively, these observations suggest 
that, in some populations, BMI might be too crude 
a measure of body fatness to accurately quantify the 
relationship between adiposity and premenopausal 
breast cancer.
Table 2 | Sex-specific risk estimates per 5 kg per m2 increase in BMI by cancer type
Cancer type Cancer subtype Number of 
cohorts
Summary risk estimate (95% CI) Refs
Men Women
Colon Adenocarcinoma 29 1.24 (1.20, 1.28) 1.09 (1.05, 1.13) 1
Rectum Adenocarcinoma 29 1.09 (1.06, 1.12) 1.02 (1.00, 1.05) 1
Oesophageal Adenocarcinoma 5 1.52 (1.33, 1.74) 1.51 (1.31, 1.74) 1
Oesophageal SCC 5 0.71 (0.60, 0.85) 0.57 (0.47, 0.69) 1
Gastric Adenocarcinoma 8 0.97 (0.88, 1.06) 1.04 (0.90, 1.20) 1
Liver HCC 9 1.19 (1.09, 1.29) 1.12 (1.03, 1.22) 18
Gallbladder Adenocarcinoma 4 1.09 (0.99, 1.21) 1.59 (1.02, 2.47) 1
Pancreatic Adenocarcinoma 23 1.13 (1.04, 1.22) 1.10 (1.04, 1.16) 7
Lung Not investigated 13 0.76 (0.70, 0.83) 0.80 (0.66, 0.97) 1
Kidney Not investigated 12 1.24 (1.15, 1.34) 1.34 (1.25, 1.43) 1
Advanced-stage 
prostate*
Not investigated 23 1.08 (1.04, 1.12) NA 17
Postmenopausal breast Not investigated 34 NA 1.12 (1.08, 1.16) 1
Premenopausal breast Not investigated 34 NA 0.92 (0.88, 0.97) 1
Endometrial Not investigated 19 NA 1.59 (1.50, 1.68) 1
Ovarian Not investigated 34 NA 1.06 (1.00, 1.12) 9
BMI, body mass index; CI, confidence interval; HCC, hepatocellular carcinoma; NA, not applicable; SCC, squamous cell carcinoma. 
*Defined differently across studies but including: American Joint Committee on Cancer stages 3 and 4; metastatic cancer; 
Whitmore–Jewett stages C and D; high grade; and Gleason grade ≥7.
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Another alternative explanation is that height squared 
in the BMI formula inadequately adjusts for height in 
women35 (height is an independent risk factor for breast 
cancer36). For example, short, obese young women may 
have a low risk of premenopausal breast cancer owing 
to their low height, even though they have high BMI37.
Associations with molecular phenotype. Increasingly, 
tumours are classified based on their molecular profile. 
Such classifications afford opportunities to enhance the 
exploration of exposure–disease associations and to infer 
specific causal pathways. Large epidemiological studies 
are now exploring these relationships and their interaction 
with BMI (summarized in TABLE 4).
For breast cancer, a relatively simple molecular classi­
fication is based on immunohistochemical expression of 
oestrogen receptor (ER) and progesterone receptor (PR). 
The evidence linking BMI and ER–PR status with breast 
cancer risk has been mounting and was initially sum­
marized in a meta­analysis published in 2009 (9 cohorts; 
22 case­control studies)38. Since then, additional findings 
from several large cohorts have been published39–44, as 
has a pooled analysis from the Breast Cancer Association 
Consortium45. ER+PR+ tumours account for approxi­
mately 60% of premenopausal breast cancers. For these 
tumours, the BMI–cancer risk associations broadly mir­
ror those seen in studies in which there are no molecular 
classifications: namely, an approximate 10% risk 
reduction for premenopausal breast cancer and 33% 
risk increase for postmenopausal breast cancer per 
5 kg per m2 BMI increment38.
For ER−PR− breast cancer risk, results have been 
mixed in postmenopausal women, but most cohort 
studies find no association39,46–49 or a reduced risk with 
increased BMI43. However, two recent studies found posi­
tive associations between increasing BMI and the inci­
dence of triple­negative tumours (that is, tumours that 
are ER−PR− and do not express human epidermal growth 
factor receptor 2 (HER2; also known as ERBB2)) in all 
study participants44 and in a subgroup of never HRT 
users42. Among premenopausal women, there may also 
be positive associations between abdominal adiposity and 
triple­negative breast cancer41. These observations suggest 
that, in terms of adiposity­driven mechanisms of tumour 
development, ER+ and ER− tumour types may share com­
mon pathways. It has been hypothesized that a large pro­
portion of ER− tumours arise from oestrogen­responsive 
precursor tumours or cells and that oestrogen sensitivity is 
lost during tumour development50. In addition, mammary 
stem cells are known to be responsive to sex hormones 
despite not having detectable expression of ER or PR51.
Endometrial cancers have long been subclassified 
into Bokhman’s type 1 endometrioid tumours (≥70%) 
and type 2 (other histology) tumours52; type 1 tumours 
are oestrogen­driven and conventionally associated 
with adiposity­driven pathways. The exact definitions 
of type 2 histological subtypes vary across the litera­
ture, but despite this we and others, through nonlinear 
piecewise meta­analysis27 and consortium analyses53, 
respectively, have shown that BMI–cancer risk associa­
tions are greater for type 1 than for type 2 endometrial 
carcinomas.
Histological classification of ovarian cancers is com­
plex and not standardized across epidemiological stud­
ies. Nonetheless, differential associations exist between 
subtypes of ovarian cancer and BMI. A pooled analysis of 
studies participating in the Ovarian Cancer Association 
Consortium (15 case­control studies) convincingly 
showed that there are no associations between BMI and 
the most common type of ovarian cancer, serous ovarian 
carcinoma (which accounts for 66% of ovarian cancer 
cases), whereas positive associations exist with less­
common histological types, such as mucinous ovarian 
carcinomas and endometrioid carcinomas of the ovary54. 
These findings are consistent with cohort studies in the 
Collaborative Group on Epidemiological Studies of 
Ovarian Cancer (17 cohorts)8.
There are at least two main classes of colorectal cancer: 
 those exhibiting microsatellite stability (MSS; 85% of 
cases) and those with microsatellite instability (MSI; 15% 
of cases). Data from three case­control studies suggest 
that positive associations between BMI and colon cancer 
are restricted to MSS tumours55–57. By contrast, pooled 
data from The Netherlands Cohort Study and Melbourne 
Table 3 | Summary risk estimates for associations between BMI and risk of selected female cancers by HRT
Cancer type 
and HRT use
Number of 
studies
Number of 
cases
I2* Forest plot RR (95% CI) Test for 
interaction‡
Refs
Postmenopausal breast cancer
Ever 6 3,732 0% 0.98 (0.94, 1.02) 26
Never 6 3,838 50.6% 1.18 (1.12, 1.25) <0.001 26
Endometrial cancer
Ever 4 791 0% 1.18 (1.06, 1.31) 27
Never 3 699 76.8% 1.90 (1.57, 2.30) 0.003 27
Ovarian cancer
Ever 34 6,120 Not reported 0.95 (0.92, 0.99) 8
Never 34 11,456 Not reported 1.10 (1.07, 1.13) <0.001 8
BMI, body mass index; CI, confidence interval; HRT, hormone replacement therapy; RR, relative risk. *I2 is a statistic used as an indicator of between-study heterogeneity. 
‡Test for interaction using meta-regression. 
RR for 5 kg per m2 increase
0.8 1 2
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Attributable risk
In epidemiology, this is the 
difference in the rate of a 
condition between an 
exposed population and  
an unexposed population.
Peripheral adipose tissue
Fat stores other than 
intra-abdominal fat (mainly 
subcutaneous fat).
Collaborative Cohort Study found no effect modification 
for colorectal cancer by MSI status and BRAF mutation 
status58. Differences may reflect lack of a universal defi­
nition for CpG island methylator phenotype (CIMP), 
which is a key determinant of microsatellite status. 
Additionally, case­control studies in colon cancer indi­
cate that tumour expression of fatty acid synthase (FASN; 
a regulator of fatty acid­derived energy metabolism) and 
β­catenin (a mediator of the WNT pathway encoded by 
CTNNB1) may modify the effect of BMI on colon cancer 
risk. Thus, the association between BMI and increased 
colon cancer risk is limited to colon tumours expressing 
FASN59 or those not expressing β­catenin60.
Taken together, and assuming that these associa­
tions are causal (discussed below), a recent study using 
the GLOBOCAN 2012 data estimated attributable risk 
and numbers of new cancer cases attributable to high 
BMI4. These analyses took account of the effect modi­
fications of country­level smoking prevalence and HRT 
use. The summary estimate reported that 3.6% of all 
new cancers in adults aged 30 years and older (exclud­
ing non­melanoma skin cancer) in 2012, or 12.8% of 
high­BMI­ associated cancers, are attributable to high 
BMI4. These figures are equivalent to an estimated 
481,000 new cancers worldwide that might have been 
caused by high BMI.
Mechanisms that explain adiposity–cancer links 
need to account for the specificities of these asso­
ciations for gender, site, histological and molecular 
subtypes; using observations such as effect modification 
may also help researchers to narrow down the specific 
mechanisms underlying these associations in certain 
cancer types.
Current hypotheses of biological mechanisms
Three hormonal mechanisms have been proposed 
to explain links between adiposity and increased 
cancer risk (FIG. 1): sex hormone metabolism, insu­
lin and IGF signalling, and adipokine pathophysi­
ology5,61–63. Subclinical inflammation has also emerged 
as important and is intimately connected to the 
adipokine system.
Sex hormone hypothesis. This hypothesis applies pre­
dominantly, but not exclusively, to postmenopausal 
breast, endometrial and ovarian cancers. In the setting 
of excess adiposity, increased risk in these cancers is 
explained by the higher rates of conversion of andro­
genic precursors to oestradiol through increased aro­
matase enzyme activity in peripheral adipose tissue — a 
process known as aromatization64. For breast cancer, 
there is abundant experimental evidence from in vitro 
and animal models that oestrogens are mitogenic and, 
indeed, mutagenic: they induce direct or indirect 
free­radical­mediated DNA damage, genetic instabil­
ity and mutations in cells in normal and neoplastic 
mammary tissues65. Altered concentrations of circu­
lating oestrogen­ related hormones are linked to breast 
Table 4 | Molecular epidemiology: associations between BMI and different molecular subtypes in prospective cohort studies
Cancer type Studies Molecular 
marker
Percentage of 
each cancer 
type in study
Risk estimate per 
5 kg per m2 BMI  
(95% CI)
Comments Refs
Premenopausal 
breast cancer
BCAC*, 
meta-analysis 
plus updated 
studies
ER+PR+ ~60* ~10% risk reduction - 39–45
ER−PR− and 
triple negative
~30* ~80% risk increase (with 
abdominal adiposity)‡
Postmenopausal 
breast cancer
BCAC*, 
meta-analysis 
plus updated 
studies
ER+PR+ ~60* ~33% risk increase - 39–45
ER−PR− and 
triple negative
~20* ~20% risk increase
ER+PR− ~15* Null association
Colon cancer CCFR MSI ~15 1.05 (0.84, 1.31) - 55
MSS ~85 1.38 (1.24, 1.54) 
P
interaction
 = 0.08
NHS FASN− 40 2.25 (1.49-3.40) FASN has an important role in 
energy metabolism of fatty acids, is 
overexpressed in some colon cancers 
and acts as a ‘metabolic oncogene’
59
FASN+ 60 1.27 (0.88, 1.83) 
P
interaction
 = 0.033
HPFS and NHS β-catenin− 54 1.84 (1.34, 2.53) β-catenin is a major mediator 
of the WNT pathway and, when 
overexpressed, contributes to tumour 
progression
60
β-catenin+ 46 1.29 (0.83, 1.71) 
P
interaction
 = 0.027
Endometrial 
cancer
Piecewise 
meta-analysis
Type I 87 2.39 (1.90, 3.03)§ Endometrioid (mucinous) 
adenocarcinoma
27
Type II 13 1.92 (1.50, 2.47)§ Papillary, clear cell, serous and other 
carcinomas
BCAC, Breast Cancer Association Consortium; BMI, body mass index; CCFR, Colon Cancer Family Registry; CI, confidence interval; ER, oestrogen receptor;  
FASN, fatty acid synthase; HPFS, Health Professionals Follow-up Study; MSI, microsatellite instability; MSS, microsatellite stability; NHS, Nurses’ Health Study;  
PR, progesterone receptor. *Percentages of tumour subtypes taken from the BCAC analysis45. ‡Model as per 10 cm increment of waist circumference41. §Risk estimates 
in the piecewise model for BMI = 32 kg per m2.
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• IGFBP1↓
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cancer risk. Specifically, the Endogenous Hormones and 
Breast Cancer Collaborative Group (EHBCCG)66 and 
the European Prospective Investigation into Cancer 
and Nutrition (EPIC) study67 reported similar find­
ings: postmenopausal breast cancer risk is increased 
(typically twofold for upper versus lowest quintiles) 
among women with higher concentrations of circulat­
ing sex hormones including dehydroepiandrosterone 
(DHEA), dehydroepiandrosterone sulfate (DHEAS), 
Δ4­androstenedione, testosterone, oestrone and 
total oestradiol, and decreased concentrations of sex 
hormone­binding globulin (SHBG). In the EHBCCG 
analysis, the association of BMI with postmenopausal 
breast cancer risk was almost entirely explained by the 
increase in oestradiol levels with higher BMI66.
Adiposity is negatively correlated with testosterone 
concentrations in men68 but positively correlated in 
women66. The EHCCBG65 and EPIC67 analyses demon­
strated that elevated blood concentrations of androgens 
are associated with increased risk of breast cancer in 
both premenopausal and postmenopausal women. Thus, 
androgens may be potential candidates linking obesity 
and breast cancer. However, the experimental evidence 
is conflicting: the conventional wisdom is that androgens 
inhibit normal breast growth but, in animal and cultured 
cell experiments, androgens may have either inhibitory 
or stimulatory effects (reviewed elsewhere64).
For endometrial cancer, increased oestradiol lev­
els not only increase endometrial cell proliferation 
and inhibit apoptosis (attributes that favour tumori­
genesis) but also stimulate the local synthesis of IGF1 
in endometrial tissue5. Indeed, the proliferative actions 
of oestradiol on endometrial tissue are mainly medi­
ated by an increase in the local production (mostly in 
uterine tissue) of IGF1. Progesterone diminishes oes­
trogenic action in the endometrium by stimulating 
oestradiol metabolism and inducing the synthesis of 
IGF­binding protein 1 (IGFBP1), which inhibits IGF1 
(REF. 69). Endometrial cancer offers an example in which 
more than one biological mechanism might link obesity 
with increased cancer risk. Similarly to studies for breast 
cancer risk, epidemiological studies support an unop­
posed oestrogen hypothesis for endometrial cancer, but 
ovarian hyperandrogenism (and concomitantly reduced 
progesterone levels) may also play a part69.
Androgens are important in the maturation of the 
prostate gland, but prospective studies assessing 
the associations between circulating sex hormone con­
centrations and prostate cancer risk have reported incon­
sistent findings. In men, compared with normal weight, 
obesity is associated with lower mean concentrations of 
serum testosterone, so how can sex hormones explain 
the observed links between obesity and advanced­stage 
prostate cancer? It is speculated that a low­testosterone 
environment (paradoxically) favours the development 
of a less­differentiated, aggressive cancer phenotype70, 
although the supporting evidence is currently limited 
and indirect. The Prostate Cancer Prevention Trial71 
reported that finasteride, which lowers dihydrotestos­
terone levels, decreased risk of well­differentiated pros­
tate cancer while simultaneously being associated with 
an increased risk of high­grade prostate cancer (Gleason 
grade ≥7). Two prospective studies72,73 reported that low 
concentrations of testosterone in serum were associated 
with a higher risk of poorly differentiated prostate can­
cer; these findings need corroboration and adjustment 
for BMI.
There are limitations to the sex hormone hypothesis. 
First, circulating sex hormone levels change cyclically in 
premenopausal women, making it challenging to meas­
ure a ‘steady state’ of risk or risk modification. Second, 
the focus is on endocrine effects, but it is increasingly 
appreciated that paracrine mechanisms are key to 
Figure 1 | Biological mechanism hypotheses. Schematic representation of the three 
main mechanisms that are hypothesized to link excess adiposity and cancer risk.  
Dashed arrows indicate indirect actions. Δ4A, Δ4-androstenedione; 17β-HSD, 
17β-hydroxysteroid dehydrogenase; E1, oestrone; E2, oestradiol; IGF1, insulin-like 
growth factor I; IGF1R, IGF1 receptor; IGFBP, IGF-binding protein; IL, interleukin;  
IR, insulin receptor; LR, leptin receptor; NF-κB, nuclear factor-κB; SHBG, sex 
hormone-binding globulin; T, testosterone; TNF, tumour necrosis factor.
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the link between adiposity and cancer risk (discussed 
below), particularly for breast cancer61,74–76. Third, there 
are multiple potential candidate sex hormones: it is 
unclear which of these are key drivers and which are 
bystanders. Fourth, the hypothesis predicts the strongest 
associations with hormone­receptor­positive (ER+PR+) 
breast cancer; however, data show that an elevated BMI 
is equally associated with ER−PR− tumours among post­
menopausal women who have never used HRT42. Fifth, 
the hypothesis is relevant for sex­hormone­sensitive 
tumours in women, but it is less clear whether it explains 
links between adiposity and advanced prostate cancer in 
men. Furthermore, it is unclear whether this hypothesis 
is applicable to tumours conventionally not included in 
the list of sex­hormone­sensitive cancers. For example, 
BMI–cancer associations are weaker in women than 
in men for colorectal cancer, and exogenously admin­
istered oestrogen­rich HRT is associated with reduced 
risk of colorectal cancer77, but whether endogenous 
physiological­ range oestrogen­related hormones offer 
some degree of attenuation of the BMI–cancer association 
in women is speculative.
Insulin resistance and IGFs. Circulating insulin levels 
positively correlate with increasing BMI, and many 
obese individuals are insulin resistant. Two decades 
ago, McKeown­Eyssen78 and Giovannucci79 suggested 
that hyperinsulinaemia may contribute to cancer develop­
ment through two pathways: direct growth­promoting 
signalling of elevated levels of insulin, and indirectly 
through what has come to be known as the insulin–IGF 
hypothesis. The latter postulates that prolonged hyper­
insulinaemia reduces production of IGFBP1 and IGFBP2 
(which normally bind IGF1 and inhibit its action), with 
resultant increases in the levels of free or bioactive IGF1 
and concomitant changes in the cellular environment 
that favour tumour development. Activation of the 
insulin receptor (IR) and IGF1 receptor (IGF1R) trig­
gers cancer­relevant intracellular signalling cascades 
including those required for mitogenesis, anti­apoptosis, 
angiogenesis and tumour­associated lymphangiogenesis, 
which favour tumour development and spread80.
In parallel, a large volume of epidemiological stud­
ies have examined the relationships between circulat­
ing total IGF1 and cancer risk. Our meta­analyses81,82 of 
these studies support relationships between total IGF1 
levels and the risk of developing prostate, colorectal, pre­
menopausal breast and postmenopausal breast cancer. 
Initial studies reported inverse associations between 
circulating levels of IGFBP3 (the signalling of which is 
thought to have anti­apoptotic effects) and cancer risk, 
but subsequent epidemiological studies did not replicate 
these findings82.
There are several shortfalls to the insulin–IGF 
hypothesis. Considering the insulin component: first, 
in epidemiological studies, the measurement of serum 
insulin levels is highly dependent on the state and dura­
tion of fasting, assay characteristics and genetic factors, 
and, accordingly, surrogates of insulin secretion (for 
example, C­peptide) or of insulin resistance (for example, 
homeostasis model assessment) are often used. It is now 
recognized that these surrogates are poor indicators of 
individual insulin resistance83. Determination of plasma 
glucose levels 2 hours after an oral glucose load is an 
alternative surrogate of insulin resistance, but currently 
the resource­heavy assessment of this exposure (as a con­
tinuous measure) with cancer has been limited to the end 
point of cancer­associated mortality in the DECODE col­
laboration84. Second, although there is a large volume of 
animal model data supporting the link between supra­
physiological levels of insulin and tumour promotion85, 
these insulin levels are not applicable in humans and the 
direct tumour­development effect attributable to insulin 
is probably very modest. Third, the biology of insulin and 
IGF1R systems is complex. Hybrid receptors of IR 
and IGF1R exist that bind insulin and IGF1, and IR may 
exist as isoform A (IR­A) and isoform B (IR­B). In many 
common adult malignancies, IR expression tends to 
be almost exclusively IR­A. IGF1 has stronger binding 
affinity for IR­A compared with IR­B and, on theoretical 
grounds, much of the direct tumour­promoting action 
of IR may be through IGF1, rather than through insulin 
binding. Finally, if insulin signalling is invoked as a candi­
date mechanism to explain adiposity and cancer risk, one 
would expect that exogenously administered insulin in 
patients with diabetes might be associated with increased 
cancer risk. Although epidemiological studies raised 
this concern in the late 2000s, it is now appreciated that 
these associations spuriously resulted from methodo­
logical limitations in the study analyses86, and they failed 
to emerge in a secondary analysis of the large ORIGIN 
trial of the long­acting insulin analogue glargine versus 
standard of care87.
Considering the IGF1 component: first, in mice, total 
levels of IGF1 increase with increasing fatness across the 
range of weights; however, this is not true for humans, 
in whom  total levels of IGF1 increase only to a BMI of 
approximately 27 kg per m2, thereafter declining with 
increasing weight88. Second, in the human circulation, 
IGF1 is heavily bound to various IGFBPs. The struc­
tural relationship of IGF1 to IGFBPs differs in tissue, 
and there is no direct evidence that circulating IGF1 
levels correlate with cellular downstream pathways at a 
tissue level. Third, a review of epidemiological studies 
has raised concerns that there may be reporting bias for 
studies describing significant associations between either 
insulin or IGF1 and cancer risk89. Finally, in overweight 
individuals who intentionally lose weight, total and free 
IGF1 concentrations tend to increase (discussed below)90.
Adipokine pathophysiology and systemic inflamma-
tion. Polypeptide hormones derived from adipocytes 
are known as adipokines91. There are more than 50 fifty 
different types of adipokines; leptin and adiponectin 
are the types most studied in the context of cancer risk. 
Adipokines are associated with the inflammatory sys­
tem; for example, leptin is a potent inflammatory agent, 
whereas adiponectin has potent anti­inflammatory 
activity.
Systemic leptin concentrations are proportional to 
the amount of body fat, as insulin induces leptin gene 
expression to signal suppression of appetite. Mean levels 
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of insulin are higher in women than in men92. Leptin is 
potentially relevant for cancer development: it has pleio­
tropic effects, it is mitogenic (notably, in breast, colon 
and prostate cancer cell lines), it is anti­apoptotic, it 
mediates immune suppression, and it is pro­angiogenic 
by itself and in synergy with vascular endothelial growth 
factor (VEGF)93,94. The leptin receptor occurs as at least 
four splice variants, but only the long form (LRb) has 
an intracellular domain of sufficient length to provide 
full signal­transducing capabilities95. LRb activates PI3K, 
MAPK and signal transducer and activator of transcrip­
tion (STAT) signalling, which are critical pathways 
involved in cell survival, proliferation and differentia­
tion62. Despite this repertoire of mechanisms, epidemi­
ological studies assessing associations between serum 
leptin concentrations and cancer risk have reported 
inconsistent findings (reviewed elsewhere96,97).
Adiponectin is the most abundant adipokine, 
secreted mainly from visceral adipose tissue (VAT). Unlike 
leptin, it is produced only by mature adipocytes. Serum 
adiponectin levels are negatively correlated with BMI 
and, in turn, insulin and oestrogens may suppress adi­
ponectin secretion98. After adjustment for BMI, serum 
concentrations of adiponectin are higher in women 
than in men, and higher in postmenopausal than in 
premenopausal women99. Of importance to tumour 
development, adiponectin may have indirect effects, 
sensitizing cells to insulin or through anti­ inflammatory 
actions. It may also have direct effects: adiponectin 
sequesters growth factors at the pre­receptor level or 
by binding to adiponectin receptor 1 (ADIPOR1) and 
ADIPOR2, activating AMP­activated protein kinase 
(AMPK) while inhibiting ERK1 and ERK2, PI3K–AKT, 
WNT–β­catenin, nuclear factor­κB (NF­κB), and Janus 
kinase 2 (JAK2)–STAT3 signalling. Collectively, these 
effects result in reduced fatty acid and protein synthe­
sis, decreased cellular growth, proliferation and DNA 
mutagenesis and increased cell cycle arrest and apopto­
sis, thus negatively influencing carcinogenesis (reviewed 
elsewhere100). Against this biological background, a com­
prehensive review100 of the epidemiological data shows 
broadly consistent inverse associations between circu­
lating adiponectin concentrations and risk of obesity­ 
associated cancers, including endometrial, breast, 
advanced prostate, colorectal, renal, and pancreatic 
(mainly in never smokers) cancers but not lung cancer 
(see Supplementary information S1 (table)).
Adiposity is associated with a state of chronic (sub­
clinical) inflammation. As adipose tissue expands, 
the levels of C­reactive protein (CRP), tumour necro­
sis factor (TNF), interleukin­1β (IL­1β), IL­6 and 
IL­18 increase101–103. An early epidemiological study 
showed an association of CRP levels with colorectal 
cancer104, but a subsequent meta­analysis of eight pro­
spective studies reported only modest correlations105. 
Later studies showed either positive associations106,107 or 
no relationship108.
Here again, there are several caveats and short­
falls. First, the molecular assembly of adiponectin is 
complex. There are three major oligomeric forms of 
adiponectin: a low­molecular­weight (LMW) trimer, 
a middle­molecular­weight (MMW) hexamer and a 
high­molecular­weight (HMW) multimer. LMW oli­
gomers are the predominant form in the circulation, 
whereas the majority of intracellular adiponectin con­
sists of HMW multimers. The ratio of HMW to LMW 
is critical to insulin sensitivity. The biological effects 
of adiponectin depend on not only relative circulating 
concentrations but also its form and the tissue­specific 
expression of its receptor subtypes (ADIPOR1 and 
ADIPOR2). Both adiponectin receptors may exist in 
tumour cells109, but more studies are needed to char­
acterize these subtypes and their functions. Second, 
studies in fatless A­Zip/F1 mice, which have unde­
tectable adipokine levels in the circulation but display 
accelerated tumour formation, suggest that adipose tis­
sue is not essential for tumour development110. Third, 
a review of epidemiological studies of biomarkers and 
subsequent cancer risk has raised concerns about 
biased reporting in studies of inflammation biomark­
ers89. Circulating levels of adipokines and inflamma­
tory markers fluctuate considerably in the presence 
of chronic diseases, differing diets, medications and 
differing levels of physical activity62,111.
Against these background inconsistencies, there 
is a continuing need to refine existing hypothesized 
mechanisms for the link between adiposity and cancer 
as well as to find additional mechanisms that explain the 
specificity of the epidemiological observations.
Weight loss and cancer-relevant biomarkers
Weight­losing interventions may affect intermediary 
biomarkers. Thus, observations from weight­losing 
studies could implicate some of the above hypotheses 
in obesity­associated cancer risk. Byers and Sedjo112 
published a comprehensive review of studies evaluat­
ing changes in cancer­relevant risk biomarkers, namely: 
oestrogens, SHBG, IGF1, IGFBPs and the inflamma­
tory markers CRP, IL­6 and TNF. Their findings were 
as follows. First, oestrogen levels drop and SHBG levels 
increase coincident with intentional weight loss, with 
about a one­third reduction in free oestradiol to be 
expected from a 10% weight loss. Second, CRP levels 
drop by about one­third after weight loss. Third, reduc­
tions in TNF and IL­6 levels are consistently seen but are 
of a smaller magnitude. Fourth, changes in levels of IGF1 
and IGFBPs are small and may be in either direction.
It is possible that the observed inconsistencies and 
small effects reflect measurement errors (in the assays) 
or chance findings in small sample sizes. An alterna­
tive and more plausible explanation is that the lack of 
substantial change in some intermediary biomarkers 
(for example, IGF1) in a cancer­protective direction, in 
the face of substantial weight reduction, argues against 
that biomarker being a key intermediary in obesity­ 
associated carcinogenesis. One recent large randomized 
trial of dietary and exercise interventions reported no 
significant changes in IGF1 and IGFBP3, despite sub­
stantial reductions in body weight in the experimental 
groups113, leading the authors to remark that: “modi­
fied IGF­1 bioavailability is unlikely to be a mechanism 
through which caloric restriction reduces cancer risk”.
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Body fat distributions and cancer risk
BMI does not fully capture the complex biology of 
adiposity. Excess body fat is a heterogeneous condi­
tion in which individuals with similar BMIs may have 
distinct metabolic and cardiovascular disease risk114. 
Variation in body fat distribution provides a poten­
tial explanation for some of the risk differential that 
persists after accounting for BMI and standard dis­
ease risk factors115. Increasingly, it is recognized that 
a proportion of overweight or obese individuals might 
not be at an increased risk for metabolic complica­
tions of obesity and have a phenotype referred to as 
metabolically healthy obesity (MHO), which contrasts 
with the metabolically unhealthy obesity (MUO) phe­
notype116. This new classification is driving treatment 
algorithms in individuals at risk of cardiovascular dis­
ease and type 2 diabetes and may have an application 
in cancer epidemiology. For example, results from the 
Framingham Heart Study117 suggest that cancer risk 
may be lower among MHO older adults than among 
MUO individuals.
Classification of types of ectopic fat. Body fat distribu­
tion differs between MHO and MUO individuals: for 
example, MHO individuals have less local ectopic fat 
than MUO individuals. The clinical importance of local 
ectopic adipose tissue depots, which surround organs 
and blood vessels or are located within organs, is now 
well recognized, as these depots are key risk factors 
for cardiovascular disease118. Thus, understanding and 
classifying ectopic fat depots (systemic and local) is 
important (FIG. 2).
Sites with predominantly systemic effects include 
VAT and intramuscular fat: these have a well­established 
role in the development of cardiovascular disease119. 
With the development of obesity, VAT is infiltrated 
Figure 2 | The roles of ectopic fat. Schematic representation of ectopic fat depots with systemic and local effects. The 
expansion of local adipocytes fuels infiltration of adipose tissue by macrophages, the phenotype of which shifts towards the 
inflammatory M1 type103. Monocyte chemoattractant protein 1 (MCP1; also known as CCL2) is a key molecule that mediates 
this macrophage infiltration138. Additionally, the number of regulatory T cells decreases while the number of CD8+ T cells 
increases, promoting further macrophage recruitment. CLSs, crown-like structures; ECM, extracellular matrix; IL-6, 
interleukin-6; TAMs, tumour-associated macrophages; TNF, tumour necrosis factor; VAT, visceral adipose tissue.
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by macrophages, and there is dysregulation of various fat­
secreting factors that are important in the development 
of a subclinical systemic inflammation state and insu­
lin resistance120. Although volumes of intrahepatic and 
intramuscular fats are much smaller than those of VAT, 
they may exert ‘overspill’ effects and contribute to sys­
temic metabolic disease, and they are key determinants 
of insulin resistance121.
In contrast to ectopic fat with predominantly sys­
temic effects, local fat depots surrounding the heart, 
blood vessels and kidneys correlate more strongly with 
metabolic disease states in the respective organs118. For 
example, pericardial fat has a stronger correlation than 
VAT has with coronary artery disease. This paradigm is 
now extending to cancer biology. For example, breast 
adipose tissue is an established ectopic fat depot with 
potential local effects on cancer development61.
Systemic ectopic fat (central adiposity) and cancer risk. 
WC was one of the earliest means of quantifying body fat 
distribution, as an approximation of central adiposity. With 
ageing, individuals lose lean body mass and gain weight as 
VAT. Metabolically active visceral fat releases substantial 
amounts of growth factors, inflammatory markers, free 
fatty acids (contributing to insulin resistance)122, locally 
produced oestrogen and adipokines, which might con­
tribute to the development of diseases, including can­
cer. In epidemiological studies, individuals with larger 
amounts of visceral fat, as identified by their larger WC, 
have a higher risk of cardiovascular disease and type 2 dia­
betes than individuals with smaller amounts of VAT. In 
turn, anthropometric measures of central adiposity (such 
as WC and WHR) correlate more strongly than BMI with 
visceral fat, and they are thought by some investigators to 
be better indicators of cancer risk123.
Early studies supported the above hypothesis. For 
example, for colorectal cancer, in prospective studies 
in which both BMI and WC (or WHR) were meas­
ured and risk estimates determined for the develop­
ment of colorectal cancer, risk seemed to be greater for 
WC in both genders124, or in women125. Furthermore, 
adjustment for BMI did not seem to attenuate associa­
tions124,125. Similarly, for postmenopausal breast cancer, 
early results from the Iowa Women Health Study126 sug­
gested a statistically significant multiplicative interaction 
between age, BMI and WHR. However, in subsequent 
reports that specifically tested interactions between WC 
and BMI, in relation to colorectal127,128 and breast40,129,130 
cancer risk, statistically significant associations were not 
found. For more recently reported prospective studies 
evaluating the risk of developing other cancers in which 
both BMI and WC (or WHR) were measured and risk 
estimates determined, summary risk estimates from 
WCRF/AICR pooled analyses were broadly similar for 
equivalent increments of BMI and WC in cancers of the 
pancreas131, endometrium132 and ovaries9, and advanced 
prostate cancer17.
Taken together, there is limited evidence that WC 
(or WHR) is a better predictor of cancer risk than BMI. 
Thus, as visceral adiposity is a key determinant of insu­
lin resistance, by extension, one would hypothesize that 
surrogates of central adiposity — for example, WC and 
WHR — are stronger predictors than BMI for cancer 
risk. However, the epidemiological evidence does not 
support this hypothesis. The current explanation is that 
WC is a poor approximation of central adiposity, as it 
captures both subcutaneous adipose tissue (SAT; which 
is typically non­ectopic) and VAT (which is typically 
ectopic) (see Supplementary information S2 (table)), and 
there is a need to develop techniques to better quantify 
these separate fat depots18.
Local ectopic fat and cancer development. The theory 
of excess adipose tissue having a local toxic effect is 
supported by multiple lines of evidence from transla­
tional research133 and epidemiology134. This theory is 
now increasingly relevant for the development of breast 
cancer and probably other types, such as hepatocellular 
carcinoma and pancreatic cancer18. The amount of fat at 
these sites is proportional to the total body fat mass18,135, 
but these fat depots retain residual independence and 
thus might be more relevant than total body adiposity 
to local tumour development. In breast cancer, the cel­
lular and metabolic makeup of the local adipose tissue 
is additionally important for tumour progression and 
metastasis (reviewed elsewhere61,136,137).
A hallmark of local ectopic fat deposition is local 
inflammation103,138 (FIG. 2). The inflammatory media­
tors secreted by macrophages not only act locally, in a 
paracrine manner, but also may contribute to general 
systemic inflammation and promote an environment 
that favours tumour development. One clear example 
of this ‘mirroring effect’ is seen in the liver (and the 
hypothesized pathway to obesity­associated hepato­
cellular carcinoma). Hepatic steatosis is the intrahepatic 
accumulation of fats, commonly as a consequence of 
obesity, and may be a driver of insulin resistance and 
systemic inflammation121,139. Nutritional insults induce 
reactive oxygen species, leading to the production 
of pro­inflammatory cytokines and the recruitment of 
immune cells to the liver, and eventually to nonalco­
holic fatty liver disease (NAFLD)140. NAFLD may pro­
gress to nonalcoholic steatohepatitis (NASH), a major 
risk factor for hepatocellular carcinoma, thus provid­
ing a possible link between obesity, insulin resistance, 
inflammation and the development of hepatocellular 
carcinoma (FIG. 3). There are several animal models that 
support this paradigm141,142. However, this process is 
not well understood, and the epidemiology is difficult 
to study143 owing to the lack of a reliable, noninvasive 
tool to quantify NAFLD and to the presence of strong 
confounders (which have often not been measured in 
the epidemiological studies of this to date), such as viral 
infection and alcohol consumption144.
Intrapancreatic fat, termed pancreatic steatosis, is 
an additional example of intra­organ fat deposition 
that increases with BMI145. Inflammation is a putative 
mechanism in the development of pancreatic cancer and 
a candidate obesity­driven pathway. In mice, excess fat 
intake leads to inflammation within the pancreas, lead­
ing to progression from normal pancreatic epithelium to 
pancreatic intraepithelial neoplasia, a precursor lesion 
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of pancreatic cancer146. Here, again, an obesity­induced 
local inflammatory microenvironment seems to be 
important. Human data are just beginning to emerge to 
support this hypothesis147.
New mechanistic hypotheses
Intriguing new biological mechanisms are beginning to 
emerge that may be additional links between obesity and 
cancer risk.
Migrating adipose progenitor cells. The tumour stroma 
includes many different mesenchymal stromal cells 
(MSCs), which are important as progenitor cells for 
the formation of, for example, endothelial cells that are 
required for neovascularization. Intriguingly, MSCs 
are present in the circulation at low levels and may be 
recruited to tumour sites by pathological signals, such 
as hypoxia or inflammation (at least in mice)148. When 
recruited to the tumour, they become tumour stromal 
cells (also known as cancer­associated fibroblasts (CAFs)) 
and promote angiogenesis and drive tumour progression. 
Bone marrow was thought to be the main source of these 
circulating progenitor cells, but evidence indicates that 
they may arise from other sources, including white adi-
pose tissue (WAT)148. In turn, WAT is expanded in obe­
sity, which may then be a link between the systemic fat 
volumes and local ectopic fat mechanisms.
The microbiome, obesity and cancer. Intestinal micro­
biota exist in a symbiotic relationship with their host, by 
metabolizing compounds that the host is unable to uti­
lize and controlling the balance of the immune responses 
in the host. However, the composition of the intesti­
nal microbiome varies with diet and pathophysio logical 
states, including obesity149. Recently developed ­omics 
technologies to capture microbial data provide new 
insights into the roles of intestinal micro organisms and 
their metabolism and, for example, suggest that the intes­
tinal microbiota contribute to colorectal carcino genesis 
(at least in mice)150, via the influence of their metabo­
lites. Importantly, it is now appreciated that gut micro­
bial metabolites ‘spill over’ into the host’s circulation 
and are involved in the pathogenesis of cancers distant 
from the gastrointestinal tract151. This field is still new 
and links with cancer remain speculative but will require 
consideration in the future.
Future directions
More-detailed measures of body fat deposition. If local 
ectopic fat deposition61 and organ­specific fat deposi­
tion are indeed relevant for cancer development, the 
challenge is now to accurately quantify these using non­
invasive modalities in large­epidemiological­scale stud­
ies, including, for example, magnetic resonance imaging 
and 1H magnetic resonance spectroscopy (illustrative 
examples are provided in Supplementary information S2 
(table)). In the Framingham Heart Study152, more than 
3,000 individuals already underwent ectopic fat quan­
tification using multi­detector computed tomography 
scanning, with correlations to cardiovascular disease 
end points152. Large­scale imaging is planned with 
the UK Biobank and the German Cohort study, with 
opportunities to correlate with cancer outcomes18.
Causal relationships and Mendelian randomization. 
Up to this point, we have assumed that the associations 
between increased adiposity and cancer risk are caus­
ally related. Statistical associations between an exposure 
and an outcome in observational epidemiology can be 
spuriously produced by common causes of the exposure 
and the outcome, an effect known as confounding153. 
An example of this might be that increased adiposity is 
caused by other risk factors that cause cancer — such 
as increased energy intake, decreased physical activity 
or increased alcohol consumption — while obesity 
per se might have no causal effect on cancer risk (dis­
cussion expanded in Supplementary information S3 
(table) using directed acyclic graphs (DAGs)). In prac­
tice, many epidemiological studies have adjusted for 
these confounders and shown that associations between 
adiposity and cancer risk remain, although residual 
unmeasured confounding may exist and adjustment 
for confounders might be only partial, as confounders 
might be measured with error.
Mendelian randomization may offer a solution to the 
problem of residual confounding, as it enables, under 
certain conditions, estimation of causal effects in obser­
vational studies using genetic variants as instrumental 
variables154. With a genetic variant taking the role of an 
instrumental variable (owing to the random assignment 
of alleles in gamete formation) one might, for example, 
estimate the average effect of the genetic variant on BMI 
difference and, in a second analysis, on disease risk. In 
turn, this would allow estimation of the increase in disease 
risk per unit increase in BMI. However, this would be pos­
sible only if the genetic variant (the instrumental variable) 
affects cancer risk only through its effect on BMI155,156 
(BOX 1). More than 50 gene loci have been associated 
with the development of obesity through genome­wide 
association studies but few Mendelian randomization 
studies have been undertaken to date157,158. These focused 
on few gene loci and cancers, including polymorphisms 
in the CYP19A1 gene (which encodes aromatase)159, 
Figure 3 | Hypothesized steatosis–hepatocellular carcinoma pathway. In the 
absence of common hepatic insults, such as excess alcohol, accumulation of fat in the 
liver (nonalcoholic fatty liver disease (NAFLD)) is associated with chronic inflammation, 
known as nonalcoholic steatohepatitis (NASH). In some subpopulations, over time, NASD 
may progress either directly to hepatocellular carcinoma or indirectly through a cirrhosis 
state. ECM, extracellular matrix; IL-6, interleukin-6; TNF, tumour necrosis factor.
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